TY  - JOUR
AU  - Ren Peng-xuan
AU  - Shang Wei-juan
AU  - Yin Wan-chao
AU  - Ge Huan
AU  - Wang Lin
AU  - Zhang Xiang-lei
AU  - Li Bing-qian
AU  - Li Hong-lin
AU  - Xu Ye-chun
AU  - Xu Eric H.
AU  - Jiang Hua-liang
AU  - Zhu Li-li
AU  - Zhang Lei-ke
AU  - Bai Fang
PY  - 2022
TI  - A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors
JF  - Acta Pharmacologica Sinica; Vol 43, No 2 (February 2022): Acta Pharmacologica Sinica
Y2  - 2022
KW  - 
N2  - The COVID-19, caused by SARS-CoV-2, is threatening public health, and there is no effective treatment. In this study, we have implemented a multi-targeted anti-viral drug design strategy to discover highly potent SARS-CoV-2 inhibitors, which simultaneously act on the host ribosome, viral RNA as well as RNA-dependent RNA polymerases, and nucleocapsid protein of the virus, to impair viral translation, frameshifting, replication, and assembly. Driven by this strategy, three alkaloids, including lycorine, emetine, and cephaeline, were discovered to inhibit SARS-CoV-2 with EC50 values of low nanomolar levels potently. The findings in this work demonstrate the feasibility of this multi-targeting drug design strategy and provide a rationale for designing more potent anti-virus drugs.
UR  - http://www.chinaphar.com/article/view/10491